Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Eltrombopag

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    54 result(s) found for: Eltrombopag. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2011-000114-19 Sponsor Protocol Number: TRC114968 Start Date*: 2011-11-29
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension). A...
    Medical condition: Thrombocytopenic Subjects with advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10060356 Acute myeloid leukaemia without mention of remission LLT
    17.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) GR (Completed) ES (Completed) IE (Completed) PL (Completed) HU (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-003166-91 Sponsor Protocol Number: CETB115E2201 Start Date*: 2019-05-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, rela...
    Medical condition: Refractory, relapsed or treatment naïve severe aplastic anemia (SAA) or recurrent aplastic anemia (AA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10002967 Aplastic anaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PT (Restarted) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000471-14 Sponsor Protocol Number: TRA105325 Start Date*: 2006-06-13
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: EXTEND (Eltrombopag eXTENded Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopa...
    Medical condition: Immune thrombocytopenic purpura (ITP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) SE (Completed) DE (Completed) ES (Completed) IE (Completed) NL (Completed) GR (Completed) FR (Completed) SK (Completed) GB (Completed) CZ (Completed) DK (Completed) IT (Completed) FI (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000452-18 Sponsor Protocol Number: ETB115J2411 Start Date*: 2018-09-26
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first-line steroids (...
    Medical condition: immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10050245 Autoimmune thrombocytopenia LLT
    22.1 100000004851 10036735 Primary thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GR (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014858-15 Sponsor Protocol Number: TRC112765 Start Date*: 2010-10-27
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR),...
    Medical condition: chemotherapy induced thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IE (Completed) GR (Completed) FI (Completed) HU (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000470-78 Sponsor Protocol Number: TRA102537 Start Date*: 2006-10-30
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administe...
    Medical condition: Idiopathic thrombocytopenic purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10051057 Idiopathic thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DK (Completed) FR (Completed) AT (Completed) CZ (Completed) SK (Completed) DE (Completed) GR (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000608-90 Sponsor Protocol Number: Eltrombo-IT-2014 Start Date*: 2014-12-15
    Sponsor Name:Fondazione IRCCS Policlinico San Matteo
    Full Title: Eltrombopag for inherited thrombocytopenias.
    Medical condition: Inherited thrombocytopenias
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004851 10043555 Thrombocytopenias HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000918-37 Sponsor Protocol Number: TRC112121 Start Date*: 2014-06-20
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high...
    Medical condition: Thrombocytopenic patients with myelodysplastic syndromes
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) GR (Prematurely Ended) IE (Prematurely Ended) BE (Prematurely Ended) NO (Prematurely Ended) ES (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-002184-17 Sponsor Protocol Number: TRA115450 Start Date*: 2012-02-08
    Sponsor Name:Glaxosmithkline Research and Development Ltd
    Full Title: A two part, double-blind, randomized, placebo-controlled and open-label study to investigate the efficacy, safety and tolerability of eltrombopag, a thrombopoietin receptor agonist, in pediatric pa...
    Medical condition: To assess the efficacy of eltrombopag, relative to placebo, in achieving platelet counts of ≥ 50 Gi/L, when administered to pediatric subjects with previously treated chronic ITP during the first 1...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10021245 Idiopathic thrombocytopenic purpura PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000292-42 Sponsor Protocol Number: TPL108390 Start Date*: 2007-12-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to asses...
    Medical condition: Thrombocytopenic subjects with hepatitis C viral infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GR (Completed) BE (Completed) ES (Completed) IT (Completed) CZ (Completed) SK (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004946-17 Sponsor Protocol Number: TPL103922 Start Date*: 2007-11-02
    Sponsor Name:GlaxoSmithKline S.A. España
    Full Title: Estudio multicéntrico aleatorizado, controlado con placebo, para evaluar la eficacia y la seguridad de eltrombopag en sujetos trombocitopénicos infectados por el virus de la hepatitis C (VHC) que, ...
    Medical condition: Sujetos trombocitopénicos con infección vírica por Hepatitic C. Thrombocytopenic subjects with hepatitis C viral infection.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) BE (Completed) NL (Completed) IT (Completed) CZ (Completed) GB (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002946-13 Sponsor Protocol Number: TRA108062 Start Date*: 2009-07-30
    Sponsor Name:GlaxoSmithKline S.A.
    Full Title: A three part, staggered cohort, open-label and double blind, randomized, placebo controlled study to investigate the efficacy, safety, tolerability and pharmacokinetics of eltrombopag, a thrombopoi...
    Medical condition: Chronic Idiopathic Thrombocytopenic Purpura Púrpura Trombocitopénica Idiopática Crónica
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) FR (Completed) NL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-002945-36 Sponsor Protocol Number: TRA108132 Start Date*: 2007-03-12
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: LENS – Long-term Eltrombopag ObservatioNal Study - A long term observational ocular safety study in adults who have received study medication (SB-497115-GR / eltrombopag olamine or placebo) in a ph...
    Medical condition: Long-term ocular safety specifically related to cataract formation in subjects who have previously participated in a phase II or III protocol for eltrombopag (SB-497715-GR)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10007739 Cataract LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) ES (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000929-37 Sponsor Protocol Number: EPAG2015 Start Date*: 2018-03-06
    Sponsor Name:GOELAMS
    Full Title: EPAG 2015 : A phase II randomized placebo-controlled study to assess the impact on outcome of Eltrombopag administered to elderly patients with acute myeloid leukemia receiving induction chemotherapy
    Medical condition: elderly patients > 60 years, with acute myeloid leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001129-15 Sponsor Protocol Number: CETB115EES03 Start Date*: 2018-08-10
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: The ELTION study – A multicenter open-label interventional study of Eltrombopag in patients with poor graft function after allogeneic hematopoietic stem cell transplantation
    Medical condition: Patients with poor graft function after allogeneic-hematopoietic stem cells transplantation (allo-HSCT). Patients diagnosed with primary or secondary poor graft function (PGF) defined as two or mo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10067862 Allogeneic stem cell transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-002658-21 Sponsor Protocol Number: CETB115JDE01 Start Date*: 2020-04-06
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A Phase II, randomized (1:1) open-label study to assess the efficacy and safety of eltrombopag in combination with dexamethasone compared to dexamethasone, as first-line treatment in adult patients...
    Medical condition: immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10050245 Autoimmune thrombocytopenia LLT
    22.1 100000004851 10036735 Primary thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001903-42 Sponsor Protocol Number: Eltrombopag-MYH9-2008 Start Date*: 2008-12-16
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: An exploratory phase II dose escalation study of eltrombopag in MYH9 related disease
    Medical condition: MYH9 related disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043551 Thrombocytopaenia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005851-40 Sponsor Protocol Number: TPL104054 Start Date*: 2008-05-07
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with C...
    Medical condition: Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008953 Chronic liver disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001371-20 Sponsor Protocol Number: 200170 Start Date*: 2013-09-06
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: Study 200170: A Rollover Study to Provide Continued Treatment with Eltrombopag
    Medical condition: Acute myelogenous leukemia & Idiopathic thrombocytopenic purpura (ITP
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000886 Acute myeloid leukemia LLT
    14.1 10005329 - Blood and lymphatic system disorders 10021245 Idiopathic thrombocytopenic purpura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) BE (Completed) GR (Completed) PL (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-004886-42 Sponsor Protocol Number: TRA114389 Start Date*: 2013-04-01
    Sponsor Name:University of Crete
    Full Title: Study of the effect of the thrombopoietin receptor agonist eltrombopag on thrombocytopenia and megakaryopoiesis of patients with lower and intermediate-1 risk myelodysplastic syndromes.
    Medical condition: Patients with lower and intermediate-1 risk myelodysplastic syndromes.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:24:42 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA